Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.
Patricia Pozo-RosichHolland C DetkeShufang WangDavid DoležilLily Q LiSheena K AuroraUwe ReuterPublished in: Current medical research and opinion (2022)
Clinicaltrials.gov identifier: NCT02614261; www.clinicaltrials.gov/ct2/show/NCT02614261.